Trial results

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

NCT07173712 on ClinicalTrials.gov · last registry update 2026-02-06

An unusually large phase 4: 324 participants, more than double the 72 typical for the stage. Due to report 30 June 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Proportion of subjects with optimal glycemic control. Sponsors move these dates routinely; any movement since this site started watching is listed below. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

NOT_YET_RECRUITING

Phase

P4

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Yanbing Li

Sponsor type

Other

Enrollment

324

Started

2026-03-15

Primary completion

2027-06-30 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Proportion of subjects with optimal glycemic control

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.